Precise point-of-care testing devices for diagnosis and prognosis of ovarian cancer

用于卵巢癌诊断和预后的精确即时检测设备

• 批准号: 451664
• 负责人: Thompson Michael
• 金额: $ 23.13万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-09-01 至 2024-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=451664&lang=en
• 关键词: Cancer Diagnostic Device; Cancer Prognostic Device; Electrochemical Biosensor; Ovarian Cancer; Point-Of-Care Testing Device

Ovarian cancer (OC) is often referred to as the "silent" killer since early-stage symptoms are not radically different from certain normal conditions. Worldwide there are 150,000 deaths, annually, and there are estimated to be more than half of a million

卵巢癌 (OC) 通常被称为“沉默的”杀手，因为早期症状与某些正常情况没有根本不同。全球每年有 15 万人死亡，估计超过 50 万人